Cargando…

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine

An Ad26.RSV.preF/RSV preF protein combination vaccine demonstrated 80.0% vaccine efficacy for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in a phase 2b study. In addition to neutralizing antibodies, Fc-effector functions are associated with protective...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartsch, Yannic C., Cizmeci, Deniz, Yuan, Dansu, Mehta, Nickita, Tolboom, Jeroen, De Paepe, Els, van Heesbeen, Roy, Sadoff, Jerald, Comeaux, Christy A., Heijnen, Esther, Callendret, Benoit, Alter, Galit, Bastian, Arangassery Rosemary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688327/
https://www.ncbi.nlm.nih.gov/pubmed/37902399
http://dx.doi.org/10.1128/jvi.00771-23
_version_ 1785152159542673408
author Bartsch, Yannic C.
Cizmeci, Deniz
Yuan, Dansu
Mehta, Nickita
Tolboom, Jeroen
De Paepe, Els
van Heesbeen, Roy
Sadoff, Jerald
Comeaux, Christy A.
Heijnen, Esther
Callendret, Benoit
Alter, Galit
Bastian, Arangassery Rosemary
author_facet Bartsch, Yannic C.
Cizmeci, Deniz
Yuan, Dansu
Mehta, Nickita
Tolboom, Jeroen
De Paepe, Els
van Heesbeen, Roy
Sadoff, Jerald
Comeaux, Christy A.
Heijnen, Esther
Callendret, Benoit
Alter, Galit
Bastian, Arangassery Rosemary
author_sort Bartsch, Yannic C.
collection PubMed
description An Ad26.RSV.preF/RSV preF protein combination vaccine demonstrated 80.0% vaccine efficacy for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in a phase 2b study. In addition to neutralizing antibodies, Fc-effector functions are associated with protective immunity against RSV. Here, vaccine-induced Fc-effector functions were evaluated for the Ad26.RSV.preF/RSV preF protein vaccine in a subset of participants enrolled in a phase 1/2a study. RSV preF-specific antibody subclasses, isotypes, Fcγ receptor binding, and Fc-effector functions were evaluated on days 1 (pre-vaccination), 15, 29, and 183. Compared with Ad26.RSV.preF or RSV preF protein alone, the combination vaccine induced greater Fc-effector functions, including antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation. Despite RSV pre-exposure, antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation were not observed at baseline but were induced de novo following vaccination. Compared with the individual vaccine components, the combination vaccine induced a more polyfunctional antibody response. IMPORTANCE: Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine.
format Online
Article
Text
id pubmed-10688327
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-106883272023-12-01 Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine Bartsch, Yannic C. Cizmeci, Deniz Yuan, Dansu Mehta, Nickita Tolboom, Jeroen De Paepe, Els van Heesbeen, Roy Sadoff, Jerald Comeaux, Christy A. Heijnen, Esther Callendret, Benoit Alter, Galit Bastian, Arangassery Rosemary J Virol Vaccines and Antiviral Agents An Ad26.RSV.preF/RSV preF protein combination vaccine demonstrated 80.0% vaccine efficacy for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in a phase 2b study. In addition to neutralizing antibodies, Fc-effector functions are associated with protective immunity against RSV. Here, vaccine-induced Fc-effector functions were evaluated for the Ad26.RSV.preF/RSV preF protein vaccine in a subset of participants enrolled in a phase 1/2a study. RSV preF-specific antibody subclasses, isotypes, Fcγ receptor binding, and Fc-effector functions were evaluated on days 1 (pre-vaccination), 15, 29, and 183. Compared with Ad26.RSV.preF or RSV preF protein alone, the combination vaccine induced greater Fc-effector functions, including antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation. Despite RSV pre-exposure, antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation were not observed at baseline but were induced de novo following vaccination. Compared with the individual vaccine components, the combination vaccine induced a more polyfunctional antibody response. IMPORTANCE: Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine. American Society for Microbiology 2023-10-30 /pmc/articles/PMC10688327/ /pubmed/37902399 http://dx.doi.org/10.1128/jvi.00771-23 Text en Copyright © 2023 Bartsch et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Vaccines and Antiviral Agents
Bartsch, Yannic C.
Cizmeci, Deniz
Yuan, Dansu
Mehta, Nickita
Tolboom, Jeroen
De Paepe, Els
van Heesbeen, Roy
Sadoff, Jerald
Comeaux, Christy A.
Heijnen, Esther
Callendret, Benoit
Alter, Galit
Bastian, Arangassery Rosemary
Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
title Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
title_full Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
title_fullStr Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
title_full_unstemmed Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
title_short Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
title_sort vaccine-induced antibody fc-effector functions in humans immunized with a combination ad26.rsv.pref/rsv pref protein vaccine
topic Vaccines and Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688327/
https://www.ncbi.nlm.nih.gov/pubmed/37902399
http://dx.doi.org/10.1128/jvi.00771-23
work_keys_str_mv AT bartschyannicc vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT cizmecideniz vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT yuandansu vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT mehtanickita vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT tolboomjeroen vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT depaepeels vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT vanheesbeenroy vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT sadoffjerald vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT comeauxchristya vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT heijnenesther vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT callendretbenoit vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT altergalit vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine
AT bastianarangasseryrosemary vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine